Literature DB >> 30266764

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.

Dusten Unruh1, Snezana Mirkov1, Brian Wray2, Michael Drumm1, Jonathan Lamano1, Yuping D Li1, Qazi F Haider1, Rodrigo Javier1, Kathleen McCortney1, Amanda Saratsis1, Denise M Scholtens3, Jann N Sarkaria4, C David James1, Craig Horbinski5,6.   

Abstract

PURPOSE: Gliomas with isocitrate dehydrogenase 1 mutations (IDH1mut) are less aggressive than IDH1 wild-type (IDH1wt) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1mut phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), F3, is among the most hypermethylated and downregulated genes in IDH1mut gliomas, correlating with greatly reduced thrombosis in patients with IDH1mut glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1mut gliomas.Experimental Design: TF expression was manipulated in patient-derived IDH1mut and IDH1wt glioma cells, followed by evaluation of in vitro and in vivo behavior and analyses of cell signaling pathways.
RESULTS: A demethylating agent, decitabine, increased F3 transcription and TF-dependent coagulative activity in IDH1mut cells, but not in IDH1wt cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1mut cells, and increased the intracranial engraftment of IDH1mut GBM164 from 0% to 100% (P = 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1wt/EGFRvIIIamp GBM6, and caused complete regression of IDH1wt/EGFRamp GBM12 (P = 0.001). In vitro and in vivo effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of β-catenin.
CONCLUSIONS: These data show that TF suppression is a component of IDH1mut glioma behavior, and that it may therefore be an attractive target against IDH1wt gliomas. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266764      PMCID: PMC6537089          DOI: 10.1158/1078-0432.CCR-18-1222

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Authors:  Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Mechanisms and biomarkers of cancer-associated thrombosis.

Authors:  Ann S Kim; Alok A Khorana; Keith R McCrae
Journal:  Transl Res       Date:  2020-07-06       Impact factor: 7.012

Review 3.  Necrotic reshaping of the glioma microenvironment drives disease progression.

Authors:  Steven M Markwell; James L Ross; Cheryl L Olson; Daniel J Brat
Journal:  Acta Neuropathol       Date:  2022-01-17       Impact factor: 15.887

4.  Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.

Authors:  Yoshinari Osada; Ryuta Saito; Satoshi Miyata; Takuhiro Shoji; Ichiyo Shibahara; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2021-07-16       Impact factor: 3.298

5.  The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.

Authors:  Patricia D B Tiburcio; Mary C Locke; Srividya Bhaskara; Mahesh B Chandrasekharan; L Eric Huang
Journal:  Transl Oncol       Date:  2020-07-01       Impact factor: 4.243

Review 6.  Beyond thrombosis: the impact of tissue factor signaling in cancer.

Authors:  Dusten Unruh; Craig Horbinski
Journal:  J Hematol Oncol       Date:  2020-07-14       Impact factor: 17.388

7.  Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.

Authors:  Dusten Unruh; Makda Zewde; Adam Buss; Michael R Drumm; Anh N Tran; Denise M Scholtens; Craig Horbinski
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

8.  Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.

Authors:  Maria Diaz; Jasmin Jo; Mark Smolkin; Sarah Jane Ratcliffe; David Schiff
Journal:  Neurology       Date:  2020-12-22       Impact factor: 9.910

Review 9.  Friend or foe-IDH1 mutations in glioma 10 years on.

Authors:  L Eric Huang
Journal:  Carcinogenesis       Date:  2019-11-25       Impact factor: 4.944

10.  Molecular Landscape of the Coagulome of Oral Squamous Cell Carcinoma.

Authors:  Marine Lottin; Simon Soudet; Julie Fercot; Floriane Racine; Julien Demagny; Jérémie Bettoni; Denis Chatelain; Marie-Antoinette Sevestre; Youcef Mammeri; Michele Lamuraglia; Antoine Galmiche; Zuzana Saidak
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.